USA - NASDAQ:AFIB - US0051111096 - Common Stock
ChartMill assigns a Buy % Consensus number of 43% to AFIB. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-08-16 | Goldman Sachs | Maintains | Neutral |
| 2022-06-24 | BTIG | Maintains | Buy |
| 2022-04-27 | BTIG | Upgrade | Neutral -> Buy |
| 2022-04-14 | Goldman Sachs | Maintains | Neutral |
| 2022-01-20 | BTIG | Downgrade | Buy -> Neutral |
| 2022-01-14 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2021-11-12 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-11-12 | Canaccord Genuity | Maintains | Buy |
| 2021-10-22 | Goldman Sachs | Initiate | Neutral |
| 2021-07-15 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2021-03-19 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021-03-19 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-03-19 | Canaccord Genuity | Maintains | Hold |
6 analysts have analysed AFIB and the average price target is 1.53 USD. This implies a price increase of 1600% is expected in the next year compared to the current price of 0.09.
The consensus rating for ACUTUS MEDICAL INC (AFIB) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.